An Effective Inhibitory Strategy of Low Steady Magnetic Field on Ovarian Cancer

Xiaodi Li  
Shanghai University of Traditional Chinese Medicine

Yanwen Fang  
Heye Health Industrial Research Institute

Zhicai Fang  
Heye Health Industrial Research Institute

Ping Wang  
Shanghai University of Medicine & Health Sciences

Jun Zhu  
National Engineering Research Center for Nanotechnology

Research Article

Keywords: Ovarian cancer, Steady-state magnetic field, Apoptosis rate, ROS, Ca2+

DOI: https://doi.org/10.21203/rs.3.rs-208755/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

To estimate the effect of a steady-state magnetic field (SMF) with low magnetic intensity gradient on the apoptosis-promoting factors related to cancer cells, we systematically select SMF with 0.2T, 0.4T and 0.6T to study their effect on different ovarian cancer lines. An in vitro cell model system about two kinds of ovarian cancer lines is established, whose viability and intracellular factors are detected by CCK-8, confocal microscopy and flow cytometry method. The results demonstrate that the apoptosis rate of ovarian cancer cells is increased with the enhancement of SMF magnetic intensity. Furthermore, we detect an increasing ROS and intracellular Ca\(^{2+}\) levels in ovarian cancer cells, which can be caused by SMF. The results suggest that ROS and Ca\(^{2+}\) levels are the main reason for the significant apoptosis of ovarian cancer cell lines in SMF. Moreover, an in vivo experiment also reveals that SMF has a strong inhibitory effect on ovarian cancer. Therefore, the inhibitory strategy is an effective, which has a great potential in the treatment of drug-resistant ovarian cancer.

Introduction

The use of magnetic therapy has been controversial for thousands of years\(^1\). Although its physiotherapy principles still lack sufficient theoretical support and are not accepted by mainstream medicine, there are many people voluntarily using magnetic therapy as an alternative and complementary therapy to prevent and treat some chronic diseases\(^2\)–\(^4\). Specially, it is well known that steady-state magnetic field (SMF) is widely used in imaging medicine\(^5\)–\(^6\). In recent decades, many scholars have studied the effects of SMF on cells including their types and the related parameters in SMF. For example, it has been proved that a negative inhibition on the proliferation of cancer cells and no or a positive effect on normal cell proliferation, and a effect of N-pole and no obvious effect of S-pole\(^7\)–\(^12\).

Based on previous reports, the magnetic intensity is a key role on cell proliferation. It has been reported that moderate intensity SMF in the tumor treatment is used as an auxiliary chemotherapy method to improve the effect of tumor chemotherapy drugs\(^8\),\(^13\)–\(^23\). However, some studies showed that a strong magnetic field of 10-13T did not affect Chinese hamster ovary cells, while a lower magnetic field of 7T significantly inhibited cell proliferation\(^13\)–\(^14\). Moreover, many researchers found that SMF affects the cells, including orientation, proliferation, microtubules, division, actin, adhesion, migration, shape and so on, by some factors of cell cycle related to chromosome and DNA, reactive oxygen species (ROS), adenosine triphosphate (ATP), and intracellular Ca\(^{2+}\) concentration, etc\(^14\),\(^24\)–\(^33\). Among them, ROS and Ca\(^{2+}\) plays an indispensable role in cells, because their intracellular levels determine most of the related factors of apoptosis\(^34\)–\(^42\). Thus, these reported results may imply that SMF can differentially affect normal ovarian and ovarian cancer cells through a precise adjusting of ROS and Ca\(^{2+}\), which reveals the potential application of SMF in the treatment of ovarian cancer.

At present experiment, to estimate the effect of SMF with low magnetic intensity on the apoptosis-promoting factors related to cancer cells, we systematically select three kinds of SMF with gradient
intensity to conduct in vitro cell experiments on two different types of ovarian cancer cell lines. Furthermore, A2780 cell is selected to establish an in vivo tumor model in mice. The result mainly explores the effect of gradient SMF on the proliferation and apoptosis of ovarian cancer cell, and on the intracellular ROS and Ca\textsuperscript{2+} concentration, which shows that SMF inhibits the proliferation and activity of ovarian cancer cells and the intracellular ROS and Ca\textsuperscript{2+} are increased significantly in ovarian cancer. Furthermore, an in vivo experiment also reveals that SMF has a strong inhibitory effect on ovarian cancer. Therefore, the inhibitory strategy is an effective, which has a great potential in the treatment of drug-resistant ovarian cancer.

**Experimental Materials**

The magnets were purchased from Hangzhou Permanent Magnet Group Co., LTD. Ovarian cancer cells of A2780 and Skov-3 were obtained from Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). PBS, FBS, and insulin were purchased from Gibco (Carlsbad, CA). Apoptosis kit was purchased from Shanghai Beyotime Institute of Biotechnology Co., LTD. DAPI staining solution was used for the macroscopic analysis of cell number changes in nucleus staining, and cck-8 assay kit was used to determine the survival rate of cells under variable conditions, both of which were purchased from Shanghai Beyotime Institute of Biotechnology Co., LTD. Fluorescent probe was applied to the analysis of intracellular ROS (DCFH-DA) content and calcium ions (Fluo-3-AM) bought level from American AAT Bioquest Inc.

**Magnetic intensity measurement**

Three magnets with magnetic intensity of 0.2T, 0.4T and 0.6T were selected for the measurement of magnetic intensity along the distance. The magnetic fluxmeter was set to zero, and then a flat table with no other magnetic field interference was selected. The measured magnet was placed in an appropriate position and measured along the center of the measured surface.

**Confocal laser observation**

Two types of ovarian cancer cells (A2780 and Skov-3) were revived in the same culture environment for a stable cell growth and proliferation. Afterwards, the four-division dish was introduced separately, and the passage of the cells was strictly counted during passage to ensure that the cell concentration and growth viability of the passage were similar. The experiment was divided into four groups, which were the normal training group (0T, control group), 0.2T, 0.4T and 0.6T of SMF training group (experimental group). 200 µL of 4×10\textsuperscript{4}/mL cell suspension was cultured under appropriate conditions (37°C, 5% CO\textsubscript{2}) for 24 hours, which was placed in a fixed magnetic environment at the surface of magnet. The cells were fixed with 4% paraformaldehyde for 30 minutes in both groups and washed with PBS buffer three times. Then they were stained with DAPI for 15 minutes and washed 3 times with PBS buffer before imaging under a confocal laser microscope with a laser range of 360–480 nm.
Cell viability experiment

A2780 and Skov-3 cells were selected to conduct in vitro experiments. Both cells (5,000 per well) were seeded in 96-well plates and incubated for 24 hours at 37°C under 5% CO₂ before the treatment. The control group was cultured under normal conditions, and the experimental group was cultured in 0.2T, 0.4T and 0.6T SMF. CCK-8 was added to each well, and then incubated at 37°C for an additional 4 hours. The amount of cell proliferation was measured by a plate reader at 450 nm. The cell viability was calculated using the following formula: viability (%) = (mean of absorbance value of treatment group/mean absorbance value of control) ×100%. The results are shown as an average of five independent measurements.

Apoptosis experiment

A2780 and Skov-3 cells respectively represented two groups, the same cells to extend equal density. The control group was cultured under normal conditions, and the experimental group was cultured in 0.2T, 0.4T and 0.6T magnetic field. After 24 hours of culture, the cells were harvested for several minutes with trypsin digestion without EDTA for 5 minutes. The cells were harvested and washed three times with PBS, and the cells were re-suspended in buffer to adjust the concentration of the control cell suspension at 10^6-10^7/mL. Afterwards, 10 µL of the apoptosis reagent propidium iodide staining solution and 5 µL of Annexin V staining solution were added and stained for 10 minutes at 4°C in the dark before the flow cytometry test.

ROS and Ca^{2+} measurements

After loading DCFH-DA fluorescent probes for 1 hour, the laser confocal microscopy tested the neutrophils ROS generation in the cell for excitation wavelength of 488 nm. The passage cells were collected separately, and then the probes were loaded. The cells were washed and re-suspended with PBS, whose concentration was adjusted to be consistent, and then the fluorescence intensity was measured by flow cytometry to relatively quantify intracellular ROS.

The Fluo-3 AM fluorescent probe was loaded during 40 minutes for the laser confocal microscopy detection of intracellular Ca^{2+} distribution of excitation wavelength of 488 nm. The passage cells were collected separately, and then the probes were loaded. The cells were washed and re-suspended with HEPES buffer, whose concentration was adjusted to be consistent. The fluorescence intensity was determined by flow cytometry to relatively quantify the intracellular Ca^{2+} level.

Growth inhibition of SMF on tumor in vivo

Animal experiments were approved by local governmental authorities and carried out in compliance with the ARRIVE guidelines. To investigate therapeutic efficacy of SMF in vivo, comparative studies of inhibiting ovarian tumor have been performed. 16 female nude mice, supplied by the Department of Experimental Animals, Shanghai Jiaotong University, were divided into four groups (a control group and three experimental groups). A2780 tumor bearing mice were established by subcutaneous injection of
about $1 \times 10^7$ (0.2 mL $\times 5 \times 10^7$ mL). Four groups including control group and experimental groups were controlled at 0, 0.2T, 0.4T and 0.6T SMF intensity. The tumor volumes were tracked every 2 days using vernier calipers from 1 day, 3 day ... until to 31 day. On the 31th day, all animals were euthanized and the tumors were dissected and weighed. All animal experiments were carried out in accordance with guidelines evaluated and approved by the ethics committee of Shanghai Jiaotong University.

**Statistical analysis**

The results are expressed as the mean ± standard deviation (SD). Statistical analysis was conducted using Student’s t-test. Differences were considered significant at $P < 0.05$.

**Results And Discussion**

As shown in Fig. 1a, we design a strategy to investigate the effective inhibitory in SMF with low magnetic intensity, on which the cells and mice are placed on the N-pole. Specially, the cells including A2780 and Skov-3 cells are incubated in a cell culture flask with 1 mm thickness to detect their factors. After the cells are injected into mice subcutaneously, the experimental tumor bearing mice are established. To ensure that the distance between the tumor and magnet surface is less than 1 mm, these mice are fixed on the surface of magnet constantly. Furthermore, a precise surface magnetic intensity is measured. As shown in Fig. 1b, three magnets with surface magnetic intensities of 0.2T, 0.4T and 0.6T are used to evaluate the relationship of their surface magnetic intensity and the distance. Figure 1c shows that the curve shape is approximate inverse function, whose intensity is decreased gradually with the increase of distance away from the magnet surface and to near zero at the distance of 10 cm no matter their initial magnetic field strength. Closer observation finds the surface magnetic intensity falls to 0.185T, 0.392T and 0.587T at the distance of 1 mm for 0.2T, 0.4T and 0.6T magnet, respectively. Based on the result, the controlled distance precisely for *in vitro* and *in vivo* model is important, leading to the same actual experimental conditions.

A2780 cells and Skov-3 cells are used to establish an *in vitro* model of ovarian cancer cells in gradient SMF. Figure 2 is the confocal microscope images of the both ovarian cancer lines under gradient SMF about 0.2T, 0.4T and 0.6T. As shown in Fig. 2, there is a big different nucleus number in the same size within the vision field in different magnetic fields. Specially, as seen from these images, the number of two kinds of ovarian cancer cell nucleus is decreased with the increasing of SMF magnetic intensity, which indicates that both ovarian cancer cells are inhibited under SMF magnetic field. Additionally, there is an abrupt inhibition under 0.6T SMF compared to that of 0.2T and 0.4T. The reason could contribute to the appearance of compensatory hyperplasia and the increase of nucleus, which leads to the aging of apoptotic cells. The results demonstrate that SMF has a very good inhibitory effect on ovarian cancer cells, revealing that SMF is a great potential treatment of ovarian cancer.

Furthermore, CCK-8 is performed to evaluate the survival rate of two kinds of ovarian cancer cells under different SMF. As shown in Fig. 3, the magnetic intensity with 0.2T, 0.4T and 0.6T can reduce the survival rate of two kinds of ovarian cancer cells. Among them, the survival rate of A2780 cells Skov-3 cells for 24
hours is decreased by 2.3%, 4.7% and 13.5%, and 2.1%, 4.68% and 10.1%, respectively, for 0.2T, 0.4T and 0.6T SMF. In other words, the inhibition degree of 0.6T SMF is about 2–4 times that of 0.2T and 0.4T SMF, which shows the largest inhibition on the survival rate of A2780 about 13.5%. Compared with Fig. 2, the results mean that high magnetic field strength is sensitive to the inhibitory effect on ovarian cancer cell lines.

To better quantify the inhibitory effect on both ovarian cancer cell lines, we perform the apoptotic rate detection experiments on two ovarian cancer lines under the same conditions. Flow cytometry analysis about two kinds of ovarian cancer cells under different SMF reveal the effect of ovarian cancer cells apoptosis on 0, 0.2T, 0.4T and 0.6T magnetic intensity for 24 hours. As shown in Fig. 4, Q1 is mechanical damaged cell, Q2 is late apoptotic or necrotic cell, Q3 is living cell, and Q4 is early apoptotic cell. Additionally, A2780 cell early apoptosis rates are 7.1%, 10.4%, 10.3% and 9.1%, late apoptosis rates are 5.1%, 11.8%, 16.5% and 25.3%, and the total apoptosis rates are 12.2%, 22.2%, 26.8% and 34.4% under control, 0.2T 0.4T and 0.6T SMF, respectively. Moreover, the early apoptosis rates of Skov-3 cell are 5.8%, 14.2%, 16.5% and 18.6%, the late apoptosis rates are 6.0%, 12.4%, 21.0% and 24.8%, and the total apoptosis rates are 11.8%, 26.6%, 37.5% and 46.1% under control, 0.2T 0.4T and 0.6T SMF, respectively. Therefore, the results prove that the effect of gradient SMF on the apoptosis of ovarian cancer cells in different lines is different, and the apoptosis rate gradually increases with the increasing SMF intensity, showing a magnetic intensity-dependent relationship of ovarian cancer.

It is generally believed that the free radical content of ROS in cells determines the oxidative senescence and death of cells, which is the key factor to promote the process of apoptosis. So, we explored the effect of SMF on the total active oxygen content of two ovarian cancer cells within 24 hours. Figure 5a is the result of ROS laser confocal microscopy images with the same inoculation concentration for two ovarian cancer lines. The DCFH-DA fluorescence intensity in a single cell is increased although the number of cells in the same area is decreased because of the external SMF according to Fig. 2. However, the quantitative analysis of the total ROS in the same concentration cells by flow cytometry is conducted, as shown in Fig. 5b. Compared with the control groups, the total ROS in A2780 cells is increased by 24.5%, 69.7% and 135.0%, respectively, and the total ROS in Skov-3 cells is increased by 17.8%, 62.5% and 112.7%, respectively. The result suggests that SMF can stimulate the production of a large number of ROS in ovarian cancer cells to promote apoptosis. The reason may be that ovarian cancer cells causes its own oxidative damage to oxidative stress of SMF, or ROS oxidizes intracellular macromolecules, destroys the normal function of macromolecules, and thus causes damage to cells and even death.

Ca²⁺ plays an indispensable role in the signaling cascade reaction between cells, and it has been proved that increased intracellular Ca²⁺ level can accelerate the apoptosis process of tumor cells. Therefore, the influence of intracellular Ca²⁺ level on two kinds of ovarian cancer lines under SMF of 0, 0.2T, 0.4T, and 0.6T for 24 hours. As shown in Fig. 6a, the laser confocal microscope shows that the number of cells in the same area is decreased and the Fluo-3 fluorescence intensity in a single cell gradually is strengthened, with the increase of SMF magnetic intensity, in both two kinds of ovarian cancer cells,
Furthermore, the total intracellular Ca\(^{2+}\) is quantitatively analyzed by flow cytometry in Fig. 6b. Compared with the control group, the intracellular Ca\(^{2+}\) level of A2780 under 0.2T, 0.4T, and 0.6T SMF is increased by 8.7%, 27.5% and 68.8%, respectively, and that of Skov-3 increases by 12.6%, 37.5% and 82.7%, respectively. The result suggests that gradient homeostasis magnetic field can stimulate Ca\(^{2+}\) influx in ovarian cancer cells or change signaling factors between ovarian cancer cells to promote apoptosis of ovarian cancer cells\(^{47}\). Thus, the intracellular Ca\(^{2+}\) level of ovarian cancer is a magnetic intensity-dependent.

As we well known, several references have reported that cancer cells may evade apoptosis through decreasing calcium influx into the cytoplasm\(^{47}\). The reasons can be mainly shown as following: on the one hand, it can be achieved either by the downregulation of plasma membrane Ca\(^{2+}\)-permeable ion channels or by the reduction of the signaling pathways to activate Ca\(^{2+}\)-permeable ion channels\(^{48,49}\). On the other hand, the defensive mechanism against apoptosis would involve the cancer cell adaptation for the reducing basal [Ca\(^{2+}\)]-endoplasmic reticulum (ER) without the induction of pro-apoptotic ER stress response that usually accompanies ER luminal calcium imbalance\(^{50}\). Therefore, in the present experiment, based on the inhibition of SMF on two kinds of ovarian cancer cells and the detection of apoptosis-related factors (ROS and Ca\(^{2+}\)) in cancer cells, we suggests that the intracellular Ca\(^{2+}\) concentration is increased stimulated by SMF, which activates the Ca\(^{2+}\)-dependent nuclear factors of activated T cells (NFAT) protein through ER luminal calcium imbalance. The results could activate Ca\(^{2+}\)-permeable ion channels. Furthermore, the activated Ca\(^{2+}\)-dependent NFAT protein can stimulate the mitochondria production of a large number of ROS in ovarian cancer cells that oxidize the key cysteine residues of transient receptor potential A1 (TRPA1) to activate proteins to promote apoptosis. Therefore, as shown in Fig. 7, ROS can synergize with Ca\(^{2+}\) to promote apoptosis in cancer cell\(^{51}\).

Furthermore, the results of *in vivo* nude mice experiments on A2780 ovarian cancer further confirm the above results. As shown in Fig. 8, different results in different treatment groups indicate that the low SMF magnetic intensity can effectively inhibit the growth and proliferation of ovarian cancer cells. It is obvious that the size of the tumor in the control group is increased significantly during the experiment. Compared with the control group, three SMF treatment groups show significant inhibitory effect on ovarian cancer of A2780 line. Among them, 0.6T SMF treatment group has the most obvious effect. As shown in Fig. 8b, the mean tumor volume of 0.6T SMF group increases most slowly among the four groups, which shows that 0.6T SMF have considerable growth inhibitory effect on tumors. Furthermore, on the 31 day, mice are sacrificed and tumors are excised for weight. The tumor photograph and their volume and weight in each group after the treatment are shown in Figs. 8a, 8b and 8c. 0.6T SMF group also shows a higher inhibition activity than that of control, 0.2T and 0.4T SMF groups. The mean tumor weight in 0.6T SMF group (0.186 ± 0.073g) is smaller than that of control group (1.170 ± 0.109g, \(P < 0.05\)), 0.2T SMF group (0.689 ± 0.098g, \(P < 0.05\)) and 0.4T SMF (0.278 ± 0.018g, \(P < 0.05\)). The results indicate that the treatment with SMF displays a significant antitumor performance. Thus, the above results reveal that SMF are a powerful candidate for combining therapy of cancer *in vivo*. 
Conclusions
In our study, an effective inhibitory strategy of SMF on ovarian cancer is reported. A low magnetic intensity of 0.2T, 0.4T and 0.6T are selected to evaluate the cell viability and tumor treatment. *In vitro* cell experiment proves that the apoptosis rate of ovarian cancer cells is increased with the enhancement of SMF magnetic intensity. The reason comes from an increasing ROS and intracellular Ca\(^{2+}\) levels in ovarian cancer cells, which means that SMF can induce ovarian cancer cells to produce large amounts of ROS free radicals to ultimately promote cell apoptosis, and also induce Ca\(^{2+}\) influx between ovarian cancer cells to interfere with signal transduction to reduce the proliferation of ovarian cancer cells. Furthermore, *in vivo* experiment also reveals that SMF has a strong inhibitory effect on ovarian cancer. And the stronger the SMF is, the better the inhibitory effect on ovarian cancer tumor is. Therefore, the inhibitory strategy is an effective, which has a great potential in the treatment of drug-resistant ovarian cancer.

Declarations

ACKNOWLEDGEMENTS
The work is supported by National Key Research and Development Project (2016YFC1303103), Shanghai Science and Technology Development Funds (19XD1431900) and Shanghai Key Laboratory of Molecular Imaging (18DZ2260400).

AUTHOR CONTRIBUTIONS

Data curation, validation and writing - Xiaodi Li and Yanwen Fang.

Conceptualization and project administration - Zhicai Fang

Funding acquisition, resources and supervision - Ping Wang and Jun Zhu.

CORRESPONDING AUTHORS

Correspondence to Ping Wang or Jun Zhu.

COMPETING INTERESTS

The authors declare no competing interest.

STATEMENT

The study is carried out in compliance with the ARRIVE guidelines.

References
1. Basford, J. R. & Jeffrey, R. A. Historical perspective of the popular use of electric and magenetic therapy. **Arch. Phys. Med. Rehab.** **82**, 1261–1269 (2001).

2. Vallbona, C., Hazlewood, C. F. & Jurida, G. Response of pain to static magnetic fields in post polio patients: A double-blind pilot study. **Arch. Phys. Med. Rehab.** **7**, 1200–1203 (1997).

3. Alfano, A. P. *et al.* Static magnetic fields for treatment of fibromyalgia: A randomized controlled trial. **J. Altern. Complem. Med.** **7**, 53–64 (2001).

4. Lew, W. Z. *et al.* Static magnetic fields enhancedental pulp stem cell proliferation by activating the p38 MAPK pathway asits putative mechanism. **J. Tissue. Eng. Regen. Med.** **10**, 233–247 (2016).

5. Victor, D. S., Malathy, E., Jason, A. K., Qian, C. & Gor’kov, P. L. Brey, W. W. In vivo chlorine and sodium MRI of rat brain at 21.1T. **Magn. Reson. Mater. Phy.** **27**, 63–70 (2014).

6. Nagel, A. M. *et al.* (39)K and (23)Na relaxation times and MRI of rat head at 21.1T. **NMR Biomed.** **29**, 759–766 (2016).

7. Albuquerque, W. W., Costa, R. M., Fernandes, T. S. & Porto, A. L. Evidences of the static magnetic field in fluence on cellular systems. **Prog. Biophys Mol. Biol.** **121**, 16–28 (2016).

8. Zhang, L. *et al.* Moderate and strong static magnetic fields directly affect EGFR kinase domain orientation to inhibit cancer cell proliferation. **Oncotarget.** **7**, 41527–41539 (2016).

9. Zhang, J., Ding, C., Ren, L., Zhou, Y. & Shang, P. The efects of static magnetic fields on bone. **Prog. Biophys Mol. Biol.** **114**, 146–152 (2014).

10. De Luka, S. R. *et al.* Subchronic exposure to static magnetic field differently affects zinc and copper content in murine organs. **Int. J. Radic. Biol.** **92**, 140–147 (2016).

11. Milovanovich, I. D. *et al.* Homogeneous static magnetic field of di fferent orientation induces biological changes in subacutely erosed mice. **Environ. Sci. Pollut. Res. Int.** **23**, 1584–1597 (2016).

12. Durmus, N. G. *et al.* Demirci, U. Magnetic Levitation of single cells. Proc. Natl. Acad. Sci. 11, E3661-E3668(2015).

13. Nakahara, T., Yaguchi, H., Yoshida, M. & Miyakoshi, J. Effects of exposure of CHO-K1 cells to a 10-T staticmagnetic field. **Radiology.** **224**, 817–822 (2002).

14. Raylman, R. R., Clavo, A. C. & Wahl, R. L. Exposure to strong static magnetic field slows the growth of human cancer cells in vitro. **Bioelectromagnetics.** **17**, 358–363 (1996).

15. Zhang, L. *et al.* X. 1T moderate intensity static magnetic field affects Akt/m TOR pathay and increases the antitumor efficacy of mTOR inhibitors in CNE 2Z cells. **Sci. Bull.** **60**, 2120–2128 (2015).

16. Ghibelli, L. *et al.* Porfiri, L. M. NMR exposure sensitizes tumor cells to apoptosis. **Apoptosis** 11, 359–365(2006).

17. Luo, Y. *et al.* Moderate intensity static magnetic fields affect mitotic spindles and increase the antitumor efficacy of 5-FU and taxol. **Bioelectrochemistry.** **10**, 31–40 (2016).

18. Gellrich, D., Becker, S. & Strieth, S. Static magnetic fields increase tumor microvessel leakiness and improve antitumoral efficacy in combination with paclitaxel. **Cancer Lett.** **343**, 107–114 (2014).
19. Gray, J. R., Frith, C. H. & Parker, J. D. In vivo enhancement of chemotherapy with static electric or magnetic fields. *Bioelectromagnetics*. 21, 575–583 (2000).
20. Sabo, J. *et al.* Effects of static magnetic field on human leukemic cell line HL-60. *Bioelectrochemistry*. 56, 227–231 (2002).
21. Hao, Q. *et al.* Effects of a moderate-intensity static magnetic field and adriamycin on K562 cells. *Bioelectromagnetics*. 32, 191–199 (2011).
22. Sun, R. G. *et al.* Biologic effects of SMF and paclitaxel on K562 human leukemia cells. *Gen. Phys. Biophys*. 31, 1–10 (2012).
23. Ghodbane, S., Lahbib, A., Sakly, M. & Abdelmelek, H. Bioeffects of static magnetic fields: Oxidative stress, genotoxic effects, and cancer studies. *Biomed. Res. Int*. 13, 1–12 (2013).
24. Kim, S. *et al.* The application of magnets directs the orientation and outgrowth in cultured human neuronal cells. *J. Neurosci. Method*. 174, 91–96 (2008).
25. Gioia, L. *et al.* Chronic exposure to a 2 mT static magnetic field affects the morphology, the metabolism and the function of in vitro cultured Sine granulosa cells. *Electromagn. Biol. Med*. 32, 536–550 (2013).
26. Li, Y. *et al.* Low strength static magnetic field inhibits the proliferation, migration and adhesion of human vascular smooth muscle cells in a restenosis model through mediating integrins betal-FAK, Ca2+ signaling pathway. *Ann. Biomed. Eng*. 40, 2611–2618 (2012).
27. Mo, W. C., Zhang, Z. J., Liu, Y., Bartlett, P. F. & He, R. Q. Magnetic shielding accelerates the proliferation of human neuroblastoma cell by promoting G1-phase progression. *PLOS ONE*. 8, e54775 (2013).
28. Wang, J. *et al.* Inhibition of viability, proliferation, cytokines secretion, surface antigen expression, and adipogenic and osteogenic differentiation of adipose-derived stem cells by seven-day exposure to 0.5 T static magnetic fields. *Stem Cells Int*. 8, 716–734 (2016).
29. Kirson, E. D. *et al.* Disruption of cancer cell replication by alternating electric fields. *Cancer Res*. 64, 3288–3295 (2004).
30. Pless, M. & Weinberg, U. Tumor treating fields: Concept, evidence and future. *Expert Opin. Investig. Drugs*. 20, 1099–1106 (2011).
31. Calabrò, E. *et al.* Effects of low intensity static magnetic field on FTIR spectra and ROS Production in SH-SY5Y neuronal-like cells. *Bioelectromagnetics*. 34, 618–629 (2013).
32. Zhao, G. P. *et al.* Cellular ATP content was decreased by a homogeneous 8.5 T static magnetic field exposure: Role of reactive oxygen species. *Bioelectromagnetics*. 32, 94–101 (2011).
33. Liboff, A. R., Williams, T., Strong, D. M. & Wistar, R. Time-varying magnetic fields effect on DNA-Synthesis. *Science*. 223, 818–820 (2018).
34. Zhang, X., Yarema, K. & Xu, A. Biological Effects of Static Magnetic Fields. Springer: Singapore. ISBN 978-981-10-3579-1 (2017).
35. Allen, R. G. & Tresini, M. Oxidative stress and gene regulation. *Free Radic. Biol. Med*. 28, 463–499 (2000).
36. Yin, C. et al. Neuroprotective effects of lotus seed pod procyanidins on extremely low frequency electromagnetic field-induced neurotoxicity in primary cultured hippocampal neurons. *Biomed. Pharmacother.* **82**, 628–639 (2016).

37. Pelicano, H., Carney, D. & Huang, P. ROS stress in cancer cells and therapeutic implications. *Drug Resist.* **7**, 97–110 (2004).

38. Liou, G. Y. & Storz, P. Reactive oxygen species in cancer. *Free Radic. Res.* **44**, 479–496 (2010).

39. Storz, P. Reactive oxygen species in tumor progression. *Front. Biosci.* **10**, 1881–1896 (2005).

40. Poniedzialek, B., Rzymski, P., Karczewski, J., Jaroszyk, F. & Wiktorowicz, K. Reactive oxygen species (ROS) production in human peripheral blood neutrophils exposed in vitro to static magnetic field. *Electromagn. Biol. Med.* **32**, 560–568 (2013).

41. Golbach, L. A. et al. Calcium homeostasis and low-frequency magnetic and electric field exposure: a systematic review and meta-analysis of in vitro studies. *Environ. Int.* **92–93**, 695–706 (2016).

42. Benquet, D. F. M. F. C., Carl, P. R. C. L. B. & Krzystyniak, P. F. S. L. K. Increased apoptosis, changes in intracellular Ca2+, and functional alterations in Lymphocytes and macrophages after in utero exposure to static magnetic field. *J. Toxicol. Env. Health-Part A.* **54**, 63–76 (1998).

43. Nowdijeh, A. A. et al. Anti-proliferative Effects of the Total Cornicabra Olive Polyphenols on Human Gastric MKN45 Cells. *Iranian. J. Biotech.* **17**, 37–45 (2019).

44. Wang, H. Z. & Zhang, X. Magnetic Fields and Reactive Oxygen Species. *Int. J. Mol. Sci.* **18**, 2175 (2017).

45. Moloney, J. N. & Cotter, T. G. ROS signalling in the biology of cancer. *Semin. Cell Dev. Biol. Acad. Press.* **80**, 50–64 (2018).

46. Rodic, S. & Vincent, M. D. Reactive oxygen species (ROS) are a key determinant of cancer's metabolic phenotype. *Int. J. cancer.* **142**, 440–448 (2018).

47. Prevarskaya, N., Ouadid-Ahidouch, H., Skryma, R. & Shuba, Y. Remodelling of Ca2+ transport in cancer: how it contributes to cancer hallmarks? *Philos. T. Roy. Soc. B: Biol. Sci.* **369**, 20130097 (2014).

48. McConkey, D. J. & Orrenius, S. The role of calcium in the regulation of apoptosis. *Biochem. Biophys. Res. Commun.* **239**, 357–366 (1997).

49. Zhivotovsky, B. & Orrenius, S. Calcium and cell death mechanisms: a perspective from the cell death community. *Cell Calcium.* **50**, 211–221 (2011).

50. Orrenius, S., Zhivotovsky, B. & Nicotera, P. Regulation of cell death: the calcium−apoptosis link. *Nat. Rev. Mol. Cell. Biol.* **4**, 552–565 (2003).

51. Wang, Q., Huang, L. & Yue, J. Oxidative stress activates the TRPM2-Ca2+-CaMKII-ROS signaling loop to induce cell death in cancer cells. *BBA-Mol. Cell Res.* **1864**, 957–967 (2017).